Stock listing

KRX:006280 GC Biopharma Corp. (녹십자) 주가

Follow GC Biopharma Corp. into a list and get an email when it puts out news.

Share price · KRX:006280

₩130,000 KRW -800 (-0.6%)

Close on Nov 20, 2026

Past year -2.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩129,500 – ₩135,000 KRWNov 20, 2026
Volume
21,215 sharesNov 20, 2026
Market cap
₩1.48T KRWAt the close on Nov 20, 2026 · price × 11.41M shares outstanding
52-week range
₩105,900 – ₩183,800 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩3.29B KRWMedian day 19,758 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
GC Biopharma Corp. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:006280 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩130,000-800-0.6%₩131,400₩135,000₩129,50021,215
₩130,800-4,200-3.1%₩133,200₩134,250₩129,50023,875
₩135,000+1,800+1.4%₩132,900₩136,800₩132,30028,218
₩133,200-800-0.6%₩134,000₩135,500₩132,20017,488
₩134,000-6,000-4.3%₩136,400₩136,800₩133,00022,334
₩140,000+1,800+1.3%₩138,100₩140,000₩133,90048,590
₩138,200+800+0.6%₩137,400₩141,000₩135,10022,721
₩137,400+700+0.5%₩138,000₩139,300₩136,10031,316
₩136,700-3,400-2.4%₩140,500₩140,800₩136,20021,316
₩140,100-2,200-1.5%₩138,500₩144,000₩135,50049,828
₩142,300+3,700+2.7%₩140,100₩145,400₩140,00060,543
₩138,600+2,300+1.7%₩136,100₩139,000₩134,10044,684
₩136,300+2,400+1.8%₩132,800₩139,800₩132,60062,229
₩133,900+3,700+2.8%₩128,100₩135,000₩128,10030,440
₩130,200-1,800-1.4%₩133,100₩133,400₩128,10025,903
₩132,000+1,500+1.1%₩130,100₩132,000₩129,60014,411
₩130,500+1,400+1.1%₩129,100₩132,700₩129,00012,863
₩129,100-500-0.4%₩129,700₩131,300₩128,40016,808
₩129,600-2,600-2.0%₩130,700₩132,900₩128,60014,259
₩132,200+1,200+0.9%₩130,900₩133,500₩129,10028,926
₩131,000-400-0.3%₩130,200₩133,000₩128,80020,320
₩131,400-1,300-1.0%₩133,300₩137,500₩130,70028,919
₩132,700+2,000+1.5%₩129,300₩134,400₩128,60029,031
₩130,700+3,100+2.4%₩127,500₩130,900₩126,60018,750
₩127,600+2,600+2.1%₩126,500₩130,600₩125,50020,186
₩125,000-2,400-1.9%₩127,900₩130,800₩123,10015,487
₩127,40000.0%₩126,800₩130,300₩125,80015,944
₩127,400-700-0.5%₩127,200₩127,500₩123,20018,861
₩128,100-1,300-1.0%₩129,200₩130,700₩127,00015,883
₩129,400-1,100-0.8%₩130,500₩130,500₩127,90030,053
₩130,500+3,000+2.4%₩129,200₩131,000₩127,70026,923
₩127,500+1,700+1.4%₩126,500₩130,500₩126,40022,805
₩125,800-3,500-2.7%₩129,100₩129,800₩124,30014,875
₩129,300+6,300+5.1%₩124,400₩129,600₩123,40033,177
₩123,000-200-0.2%₩123,800₩124,700₩121,30021,185
₩123,20000.0%₩124,300₩124,600₩121,40012,951
₩123,200-100-0.1%₩123,400₩124,800₩122,60012,578
₩123,30000.0%₩123,800₩125,400₩123,10014,262
₩123,300-2,400-1.9%₩125,700₩126,300₩123,10018,851
₩125,700+3,300+2.7%₩122,000₩126,500₩121,90018,164
₩122,400-300-0.2%₩124,200₩124,200₩120,700117,126
₩122,700+300+0.2%₩123,600₩124,200₩122,00012,744
₩122,400-2,500-2.0%₩126,000₩126,300₩121,60017,432
₩124,900-1,700-1.3%₩126,300₩127,400₩124,80015,789
₩126,600-1,700-1.3%₩127,100₩128,000₩124,80015,217
₩128,300-1,800-1.4%₩128,300₩131,100₩127,20020,355
₩130,100+2,700+2.1%₩126,100₩130,100₩125,40026,875
₩127,400+400+0.3%₩127,000₩127,700₩126,10015,358
₩127,000-300-0.2%₩128,400₩128,500₩126,10017,150
₩127,300-300-0.2%₩128,800₩128,800₩125,70013,558
₩127,600+600+0.5%₩128,200₩128,800₩125,5009,199
₩127,00000.0%₩127,900₩131,300₩125,70017,766
₩127,000-1,100-0.9%₩127,800₩131,900₩126,70019,181
₩128,100-1,000-0.8%₩127,900₩129,300₩127,20013,517
₩129,100-1,400-1.1%₩128,900₩129,300₩125,70017,348
₩130,500+3,400+2.7%₩126,300₩130,600₩125,50018,676
₩127,100-3,400-2.6%₩130,600₩130,900₩126,20015,160
₩130,500+4,200+3.3%₩129,100₩131,000₩127,10019,330
₩126,300-4,000-3.1%₩127,600₩129,500₩124,00021,796
₩130,300+8,200+6.7%₩124,900₩131,100₩124,20041,331
₩122,100-3,300-2.6%₩122,800₩123,700₩120,00029,371
₩125,400+4,400+3.6%₩133,500₩133,800₩123,70065,683

Splits

1 split · KRX:006280 · every price before a split is adjusted for it

DayRatioWhat
21-for-20Split
Ticker
KRX:006280
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
KRX
Currency
KRW

What changed lately

Latest news

All GC Biopharma Corp. news

GC Biopharma Corp. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
9 in the last 12 months · 23 in all · newest Aug 24, 2026 · oldest 2025
Decks
3 decks · latest Jan 31, 2024

Valuation

EV/sales 0.9× against a median of 3.8×: the lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩1.75T KRW
P/E
Loss
EV/sales
0.9×
EV/EBITDA
13.2×
Price/book
1.2×
Gross margin
26.4%
Operating margin
2.4%
Net margin
−2.5%
Debt to equity
0.3×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
GC Biopharma Corp. · KRX:006280US$1.10BUS$1.30Bn/a0.9×13.2×1.2×−2.5%0.3×n/a
Hualan Biological Vaccine Inc. Class A · SZSE:301207US$1.16BUS$845.9M167×8.1×n/a1.5×6.6%0.0×n/a
Chongqing Lummy Pharmaceutical Co., Ltd. Class A · SZSE:300006US$1.15BUS$1.04Bn/a9.6×n/a4.5×−16.6%0.1×n/a
Idorsia Ltd. · SIX:IDIAUS$1.15BUS$2.66Bn/a10.2×n/an/a−128.8%n/an/a
Harrow, Inc. · NASDAQ:HROWUS$1.14BUS$1.36Bn/a4.5×188×39.1×−9.4%10.0×1.31
Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550US$1.12BUS$929.9M32.3×4.1×n/a2.7×15.3%0.0×n/a
Vetoquinol SA · EURONEXT:VETOUS$1.09BUS$848.6M17.4×1.5×7.0×1.6×10.9%0.0×n/a
North China Pharmaceutical Company Ltd. Class A · SSE:600812US$1.09BUS$1.55B81.1×1.3×n/a1.3×1.1%0.8×n/a
Basilea Pharmaceutica AG · SIX:BSLNUS$1.07BUS$964.2M22.4×3.5×15.2×5.6×17.3%0.5×n/a
Tianjin Ringpu Bio-technology Co., Ltd. Class A · SZSE:300119US$1.06BUS$873.7M21.0×1.6×n/a1.5×9.6%0.1×n/a
Beijing Foyou Pharma Co., Ltd. Class A · SSE:601089US$1.03BUS$710.8M18.7×1.3×n/a1.8×10.2%0.0×n/a
Median of the othersUS$1.11BUS$947.1M22.4×3.8×15.2×1.8×8.1%0.1×1.31

Forecasts

Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
192250.00 KRW · Analysts' mean
EPS, year to Dec 2026
17290.16 · 4 analysts
Revenue, year to Dec 2026
1.9T · 3 analysts

Events

Next results
Jan 25, 2027 (expected)
QuarterResultsShare move
Quarter to Sep 30, 2026Nov 16, 2026 · Before open−0.6%
Q2 2026Aug 14, 2026 · Before open−0.2%
Q1 2026May 15, 2026 · Before open−4.2%
Q4 2025Mar 18, 2026−2.1%
Q3 2025Nov 14, 2025 · Before open+0.1%
Q2 2025Aug 14, 2025 · Before open−0.6%
Q1 2025May 15, 2025 · Before open+2.5%
Q4 2024Mar 18, 2025+4.0%
Q3 2024Oct 30, 2024 · After close+1.8%
Q2 2024Aug 5, 2024 · After close+10.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close−1.9%
Q4 2023Jan 31, 2024 · After close+1.7%
Q3 2023Nov 1, 2023 · After close+1.2%
Q2 2023Aug 1, 2023 · After close−0.4%
Q1 2023May 2, 2023 · After close−1.9%
Q4 2022Feb 14, 2023 · After close−4.6%
Q3 2022Nov 1, 2022 · After close+3.1%
Q2 2022Aug 1, 2022 · After close−1.8%
Q1 2022May 2, 2022 · After close−3.1%
Q4 2021Feb 14, 2022 · After close−7.3%

Open Events

Decks

DeckKindSlidesDate
Investor Day (January 2024)Investor day14 slidesJan 31, 2024
Investor Day (January 2024)Investor day13 slidesJan 31, 2024
FY2023 Earnings PresentationEarnings5 slidesJan 31, 2024

Open Decks

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.99T1.68T1.63T1.71T1.54T1.50T1.37T1.33T1.29T1.20T
Cost of revenue1.44T1.20T1.14T1.13T1.02T1.06T997.4B989.0B921.1B845.8B
Gross profit554.1B481.9B484.6B581.8B520.6B440.6B372.3B345.9B366.8B352.1B
Research and development152.9B166.2B173.5B191.3B146.0B138.0B126.7B122.0B108.6B112.3B
Selling, general and administrative166.3B130.1B134.4B165.1B169.1B145.2B112.3B92.2B84.4B82.3B
Operating income69.1B32.1B34.4B81.3B73.7B50.3B40.3B50.2B90.3B78.5B
Depreciation and amortization87.7B81.0B75.9B65.1B55.9B48.8B46.7B40.1B36.7B31.1B
EBITDA156.8B113.1B110.3B146.4B129.6B99.1B87.0B90.4B127.0B109.5B
Interest expense50.3B40.4B28.5B18.4B12.5B10.4B9.61B7.61B00
Income before tax-35.3B-41.1B-27.1B85.7B172.6B104.5B-6.14B50.2B72.2B79.5B
Income tax35.6B15.4B5.15B15.9B15.4B14.4B
Net income-4.67B-26.3B-26.6B65.5B123.2B81.0B-3.64B34.4B53.2B63.0B
Earnings per share, basic-409.51-2,302.62-2,333.425,734.8710,795.577,101.34-318.723,016.644,665.36

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents49.4B22.6B49.7B105.4B186.1B232.3B98.5B96.6B171.0B56.9B
Short-term investments1.43B1.43B5.80B6.94B16.9B23.2B43.1B10.1B268.0M60.3B
Receivables402.7B386.5B437.0B394.2B413.8B402.1B405.2B391.2B368.2B345.0B
Inventory891.6B746.6B516.2B442.4B455.0B437.1B406.6B386.9B381.3B320.8B
Current assets1.37T1.20T1.04T980.4B1.09T1.13T961.8B893.4B926.5B801.4B
Property, plant and equipment899.8B751.1B718.7B559.7B552.0B554.0B
Goodwill118.1B125.6B142.5B142.5B142.5B10.1B10.1B10.2B15.1B17.8B
Total assets2.97T2.74T2.64T2.53T2.46T2.15T1.96T1.72T1.70T1.55T
Accounts payable177.3B156.8B143.8B121.3B119.5B134.8B139.3B144.9B158.8B118.3B
Current liabilities1.15T769.5B868.9B540.7B552.9B589.4B401.4B303.5B260.1B303.3B
Long-term debt253.5B339.5B84.9B278.8B280.3B194.2B272.1B263.3B307.0B149.5B
Total liabilities1.58T1.26T1.10T958.9B962.4B882.1B775.2B597.2B594.9B491.6B
Shareholders' equity1.22T1.25T1.30T1.33T1.27T1.12T1.05T1.06T1.04T993.1B
Shares outstanding11.4M11.4M11.4M11.4M11.4M11.4M11.4M11.4M11.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations99.5B-53.5B-5.47B119.2B126.0B36.0B40.3B14.4B57.9B-1.74B
Capital spending-105.3B-42.4B-126.0B-94.7B-102.3B-82.9B-127.5B-41.4B-29.5B-98.7B
Free cash flow-5.82B-95.9B-131.5B24.5B2.44B-65.4B-107.3B-50.6B2.31B-100.4B
Cash from investing-132.1B29.7B-177.9B-86.1B14.8B-111.1B
Cash from financing-41.3B81.0B140.8B-4.51B48.2B110.6B
Dividends paid-18.8B-19.5B-24.8B-24.0B-18.5B-12.7B-12.4B-15.3B-15.3B-20.5B
Share buybacks-21.8B
Change in cash26.8B-27.1B-55.7B-80.7B-46.2B133.8B1.83B-74.3B114.1B-816.1M

Open Financials

Cap table

Built by 6ix from GC Biopharma Corp.’s releases

Common shares
11,413,127
Fully diluted
11,413,127

Fully diluted

LineShares
Common shares11,413,127

Share count over time

CountShares
Nov 22, 202611,413,127

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Vanguard Total International Stock Index Fund79,614US$6.43MNo changeJul 31, 2026
iShares Core MSCI Emerging Markets ETF71,520US$6.71M+22May 31, 2026
Old Westbury Small & Mid Cap Strategies Fund65,254US$5.27MNo changeJul 31, 2026
Vanguard Developed Markets Index Fund52,610US$4.1MNo changeJun 30, 2026
Nuveen Quant International Small Cap Equity Fund31,553US$2.55MNewJul 31, 2026
Emerging Markets Core Equity 2 Portfolio29,352US$2.37M−648Jul 31, 2026
College Retirement Equities Fund - Total Global Stock Account24,362US$1.9M+19,619Jun 30, 2026
Dimensional Emerging Markets Value Fund20,986US$1.69M+11,081Jul 31, 2026
Schwab International Equity ETF18,578US$1.74M+338May 31, 2026
Vanguard Ftse All-World Ex-Us Index Fund12,314US$994KNo changeJul 31, 2026
All 43 holders
HolderSharesValueChangeAs of
iShares Core MSCI Total International Stock ETF11,584US$935KNo changeJul 31, 2026
The Emerging Markets Small Cap Series11,208US$905KNo changeJul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF7,693US$625K+778Jul 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF7,015US$544K−8Jun 30, 2026
Vanguard Pacific Stock Index Fund5,785US$467KNo changeJul 31, 2026
Dimensional Emerging Core Equity Market ETF4,676US$380KNo changeJul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF4,588US$373KNo changeJul 31, 2026
Franklin FTSE South Korea ETF4,186US$325K+2,476Jun 30, 2026
WisdomTree Emerging Markets SmallCap Dividend Fund4,070US$316K−45Jun 30, 2026
Vanguard Total World Stock Index Fund4,046US$327KNo changeJul 31, 2026
Fidelity Total International Index Fund3,489US$278KNo changeJul 31, 2026
Dimensional Emerging Markets Value ETF3,155US$256K−71Jul 31, 2026
Avantis Emerging Markets Equity ETF2,501US$235KNo changeMay 31, 2026
Emerging Markets Social Core Equity Portfolio1,952US$158KNo changeJul 31, 2026
Emerging Economies Fund1,905US$179K−2,780May 31, 2026
World ex U.S. Core Equity Portfolio1,607US$130K+227Jul 31, 2026
iShares MSCI Emerging Markets Small-Cap ETF1,358US$127K−208May 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio1,262US$97,910No changeJun 30, 2026
Parametric Tax-Managed Emerging Markets Fund1,257US$98,067No changeJun 30, 2026
Emerging Markets ex China Core Equity Portfolio1,123US$90,635−169Jul 31, 2026
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETF1,122US$90,554−34Jul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio981US$79,175No changeJul 31, 2026
Vanguard ESG International Stock ETF903US$84,714No changeMay 31, 2026
Avantis Emerging Markets Small Cap Equity ETF633US$59,384No changeMay 31, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF541US$43,980No changeJul 31, 2026
World ex U.S. Targeted Value Portfolio484US$39,063−178Jul 31, 2026
Dimensional Emerging Markets ex China Core Equity ETF346US$28,128+45Jul 31, 2026
Dimensional World ex U.S. Sustainability Targeted Value Portfolio307US$24,777No changeJul 31, 2026
Emerging Markets Targeted Value Portfolio273US$22,033No changeJul 31, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund138US$11,218No changeJul 31, 2026
SA Emerging Markets Value Fund119US$9,232No changeJun 30, 2026
Avantis Emerging Markets ex-China Equity ETF101US$9,475+1May 31, 2026
Franklin FTSE Asia ex Japan ETF21US$1,629No changeJun 30, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about GC Biopharma Corp.